Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis
  • Francisco Javier Teigell Muñoz
    Department of Internal Medicine, Infanta Cristina University Hospital, Madrid, Spain
  • María Mateos-González
    Department of Internal Medicine, Infanta Cristina University Hospital, Madrid, Spain https://orcid.org/0000-0002-8466-4239
  • Elsa Bernal-Hertfelder
    Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • Ana Sánchez de Torre
    Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • María García-Ferrón
    Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • Carmen de Cáceres Velasco
    Department of Hospital Pharmacy, Infanta Cristina University Hospital, Madrid, Spain https://orcid.org/0000-0002-6607-3267
  • Coralia Bueno Muiño
    Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain https://orcid.org/0000-0002-1614-1030

Keywords

Infective endocarditis, dalbavancin, Enterococcus, outpatient parenteral antimicrobial therapy, OPAT

Abstract

Infective endocarditis is a relatively uncommon infection that requires a high index of suspicion, which can sometimes delay its diagnosis. It requires several weeks of intravenous antibiotics, which traditionally requires long hospital stays. Dalbavancin is a novel antibiotic with high activity against several Gram-positive pathogens. Its weekly administration allows the outpatient management of complicated infections requiring parenteral treatment, but only a few cases of Enterococcus faecalis endocarditis treated with dalbavancin have been reported in the literature. We here report a case of successful treatment with dalbavancin of an infectious endocarditis caused by E. faecalis.

VIEW THE ENTIRE ARTICLE

References

  • Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075.
  • Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 2018;67(5):795–798.
  • Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 2019;18(1):30.
  • Herrera-Hidalgo L, de Alarcón A, López-Cortes LE, Luque-Márquez R, López-Cortes LF, Gutiérrez-Valencia A, et al. Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives. Antibiotics (Basel) 2020;9(10):657.
  • Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40(3):374–380.
  • Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 2020;9(10):700.

    • Views: 492
    HTML downloads: 77
    PDF downloads: 343

    Published: 2023-02-03
    Issue: 2023: Vol 10 No 1 (view)

    How to cite:
    1.
    Teigell Muñoz FJ, Mateos-González M, Bernal-Hertfelder E, Sánchez de Torre A, García-Ferrón M, de Cáceres Velasco C, Bueno Muiño C. Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis . EJCRIM 2023;10 doi:10.12890/2023_003654.